Blood B cells from eight patients with clonal lymphoid disorders characterized by monoclonal IgM secretion (four with malignant plasmacytic proliferation typical of Waldenstrom macroglobulinemia and four without overt lymphoid neoplasia) were found to spontaneously differentiate in vitro into plasma cells. In all instances, monoclonal plasma cells (8-45% of the cells) were generated from extensively purified B cells or T-cell-depleted peripheral blood mononuclear cells after a 7-day culture period, with a corresponding high rate of IgM secretion into the culture medium. This differentiation occurred in the absence of any cell proliferation process as measured by [3H]thymidine uptake at day 2 or 4. Normal B cells did not differentiate under the same experimental conditions. Detection of interleukin 6 (IL-6) bioactivity in all patients' B-cell culture supernatants as well as of IL-6 mRNA in freshly prepared, uncultured B cells in the two cases studied by in situ hybridization suggested that IL-6 secretion by B cells may play a role in this process. Moreover, in the four patients without overt lymphoid proliferation, B-cell differentiation was significantly inhibited (60-80%) in the presence of anti-IL-6 antibodies. In contrast, anti-IL-6 antibodies did not preclude the differentiation into plasma cells of B cells from the four patients with bona fide Waldenstrom macroglobulinemia. These results suggest a two-step pathogenesis for such human lymphoplasmacytic clonal proliferations, the initial stage being characterized by an IL-6-dependent autocrine differentiation pathway.
ABSTRACT
Blood B cells from eight patients with clonal lymphoid disorders characterized by monoclonal IgM secretion (four with malignant plasmacytic proliferation typical of Waldenstrom macroglobulinemia and four without overt lymphoid neoplasia) were found to spontaneously differentiate in vitro into plasma cells. In all instances, monoclonal plasma cells (8-45% of the cells) were generated from extensively purified B cells or T-cell-depleted peripheral blood mononuclear cells after a 7-day culture period, with a corresponding high rate of IgM secretion into the culture medium. This differentiation occurred in the absence of any cell proliferation process as measured by [3H] thymidine uptake at day 2 or 4. Normal B cells did not differentiate under the same experimental conditions. Detection of interleukin 6 (IL-6) bioactivity in all patients' B-cell culture supernatants as well as of IL-6 mRNA in freshly prepared, uncultured B cells in the two cases studied by in situ hybridization suggested that IL-6 secretion by B cells may play a role in this process. Moreover, in the four patients without overt lymphoid proliferation, B-cell differentiation was significantly inhibited (60-80%) in the presence of anti-IL-6 antibodies. In contrast, anti-IL-6 antibodies did not preclude the differentiation into plasma cells of B cells from the four patients with bona fide Waldenstrom macroglobulinemia. These results suggest a two-step pathogenesis for such human lymphoplasmacytic clonal proliferations, the initial stage being characterized by an IL-6-dependent autocrine differentiation pathway.
Interleukin 6 (IL-6) has pleiotropic effects on cells from various lineages. Alone or in synergy with other lymphokines, IL-6 triggers the production ofacute-phase proteins by hepatocytes (1) , the proliferation of T cells (2, 3) , the differentiation of cytotoxic T cells (4) , and the proliferation and differentiation of hematopoietic precursors (5). IL-6 has two distinct effects on B cells, since it drives activated B cells to terminal plasma-cell differentiation, as originally described (6) , and also behaves as a murine plasmacytoma or hybridoma growth factor (7, 8) . The latter effect may be significant in the development and/or maintenance of malignant plasma cells in human multiple myeloma (9) . Here we provide evidence that IL-6 may also have a key role in the development of lymphoid disorders characterized by secretion of monoclonal IgM.
MATERIALS AND METHODS
Patients. The eight patients studied had a serum monoclonal IgM. Four suffered from a malignant lymphoplasmacytic proliferation typical of Waldenstrom macroglobulinemia, whereas the other four showed no evidence of overt lymphoid neoplasia. The tTo whom reprint requests should be addressed.
3309
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
3310
Medical Sciences: Levy et al. (15, 16) . In brief, cells were centrifuged onto glass slides and immediately fixed in 4% paraformaldehyde. Preparations were then transferred into a solution of 70% ethanol and stored at 40C until used. The IL-6 probe (ref. 17 ; a gift from C. Vaquero and J. Sanceau) used in the present studies was a 700-base-pair Xmn I-Ban I insert of human IL-6 cDNA cloned into the pGEM-4 plasmid (Promega) by standard methods (18) . As negative controls the sense IL-6 probe and control template were used (19) . Run-off transcripts of appropriate linearized plasmids were synthesized using T7 RNA polymerase according to the supplier's instructions (Promega) (Fig. 1 C and D) . Before culture, clg-containing cells accounted for <1% of the cell preparations. In our experimental conditions, Tcell-depleted PBMCs or purified B cells from healthy individuals did not differentiate (<1% plasma cells). When studied with monospecific antibodies to heavy and light chains, >99% plasma cells in the patients' cultures were stained with anti-,u reagents and displayed a single light-chain isotype. In three patients whose IgM was directed to MAG, quantitative ELISAs showed that most if not all of the secreted IgM possessed this antibody activity.
This differentiation of B cells occurred early in the culture period, since as early as day 3 the percentage ofcIg-containing cells represented around half of that observed at day 7. Importantly, the differentiation event occurred without a detectable increase in [3H]thymidine incorporation (<500 cpm) measured at days 2 and 4 in the three cases studied.
IL-6 Dependence of Spontaneous B-Cell Differentiation. To investigate the possible role of IL-6 in the spontaneous differentiation of B cells, we assayed the culture supernatants for IL-6 activity and studied the effects of addition of anti-IL-6 antibodies to the culture medium.
Supernatants from purified B cells were collected at days 1 and 3 and serial dilutions were assayed for the ability to induce proliferation of the IL-6-dependent 7TD1 cell line. In all patients' samples studied, bioactive IL-6 (40-200 units/ ml) was detected, whereas no or barely detectable IL-6 activity was found in supernatant from normal blood B cells (Fig. 2) . In one experiment, purified B cells were submitted to a further step of monocyte depletion, by complementdependent cytotoxicity with CD11 mAb; the level of IL-6 in the culture supernatant was not reduced by this treatment.
Various anti-IL6 antibodies were added to T-cell-depleted PBMCs (four cases) or purified B cells (four cases) at the onset of cultures to study their effects on plasma-cell generation. A 60-82% decrease in the number of cIg-containing cells was noted when cells (one T-cell-depleted preparation and three purified B-cell preparations) from the four patients without overt malignant proliferation were studied (Fig. 1A) . On the other hand, no inhibition of B-cell differentiation occurred with cells (three T-cell-depleted preparations and one purified B-cell preparation) obtained from the four patients with Waldenstrom macroglobulinemia (Fig. 1B) . These results were corroborated in another set of experiments, by the measurement of IgM concentration in the culture supernatants collected at day 7 ( Fig. 1 C and D) .
As could be expected from the kinetics of plasma-cell generation (see above), the addition of rabbit anti-IL-6 antibodies at day 3 or 6 had only marginal inhibitory effects. Finally, addition of recombinant IL-6 (10 ng/ml) at the onset of the culture period did not enhance the development of plasma cells either in patients' (three cases) or in normal donors' (two cases) cell preparations.
Detection of IL-6 mRNA. Purified uncultured B cells were prepared from a normal donor and two patients without overt lymphoid proliferation. In situ hybridization was performed using the antisense IL-6 probe, with both the A probe and the sense IL-6 probe as controls. A low number of silver grains per cell (<15) was found when the three cell preparations were hybridized with control probes or when normal B cells were hybridized with the antisense IL-6 probe. In contrast, 30 -50%o of B lymphocytes from both patients were signifi- cantly labeled by the antisense IL-6 probe (25-40 grains per cell) (Fig. 3) . DISCUSSION Waldenstrom macroglobulinemia is characterized by the presence of a serum monoclonal IgM and a pleiomorphic monoclonal lymphoid infiltration of bone marrow and peripheral lymphoid organs by small lymphocytes, lymphoplasmacytic cells, and plasma cells (20) . Hence, in this disease, the proliferating clonal B cells retain some capacity for terminal maturation into plasma cells, unlike B cells from most other lymphoproliferative diseases (such as chronic lymphocytic leukemias or B-cell lymphomas), which are believed to be frozen at a given step in the B-cell differentiation pathway. On the other hand, the presence of a monoclonal IgM in the serum is not invariably associated with an overt B-cell lymphoid proliferation. The latter may, however, become apparent after several years in some patients with a long follow-up, because the clinical consequences of the autoantibody activity of their serum monoclonal IgM led to A B FIG. 3 . Detection of IL-6 mRNA by in situ hybridization on uncultured purified B cells from a patient with monoclonal IgM (A) or from a healthy donor (B). (x93.) P its early discovery. This course has been observed, for instance, in patients with autoimmune hemolytic anemia and monoclonal IgM with cold agglutinin activity (21) and in patients with a peripheral neuropathy and serum monoclonal IgM directed to MAG (22) . Whether these diverse clinicopathological patterns associated with monoclonal IgM correspond to two successive stages of the same lymphoproliferative process remains unsettled. In both instances, clonal B cells are often present in blood (20, 23) and may exhibit unusual phenotypic features such as the expression of the PCA1 antigenic marker (24) .
We show here that T-cell-depleted or highly purified blood B cells from patients with serum (25) . However, the significance of the presence of IL-6 mRNA in these diseases is unknown.
In this study, we obtained evidence that the secreted IL-6 plays a major role in the process of terminal plasma-cell differentiation of the cultured B cells from those patients without overt underlying B-cell malignancy, since their differentiation was significantly inhibited in the presence of anti-IL-6 antibodies. Although we cannot formally rule out a synergism between IL-6 and other lymphokines in the differentiation process, it should be noted that the supernatants did not contain measurable IL-1, IL-2, IL-4, or IL-5 activities (data not shown) and that we used highly purified B cells. In sharp contrast with the above results, the addition of anti-IL-6 antibodies did not inhibit the differentiation of B cells from patients with overt lymphoid malignancy. These findings might have important implications for the pathogenesis of Waldenstrom macroglobulinemia, since they suggest that this lymphoproliferative disorder may evolve in two distinct phases, an initial stage characterized by an IL-6 autocrine differentiation pathway and a second, truly neoplastic one, independent of secreted IL-6. This natural history would bear some analogies with the evolution of some T-cell malignancies associated with human T-cell leukemia virus type I: these malignancies may be initially dependent on an IL-2 autocrine growth, whereas later the cells still express IL-2 receptors constitutively but exhibit an IL-2-independent proliferation (26, 27) .
Normal resting B cells neither produce IL-6 nor respond to this lymphokine (6, 25, 28) , as confirmed in our control experiments. Only the triggering of B-cell surface immunoglobulin by anti-immunoglobulin antibodies has been shown so far to induce the synthesis of IL-6 mRNA (25 
